Consensus review outlines diagnostic and management protocols in tyrosinemia type I, highlighting the importance of newborn succinylacetone screening and early NTBC treatment.
Key Points
To establish evidence- and consensus-based clinical recommendations for the uniform identification, diagnosis, and treatment of tyrosinemia type I.
A panel of 11 clinical specialists from the United States and Canada (eight biochemical genetics physicians, two metabolic dietitians, and one clinical psychologist) was assembled.
Evidence and expert consensus were gathered via a comprehensive literature review, a practitioner management survey, and a nominal group process across two face-to-face meetings.
Strong consensus supported universal newborn screening using blood succinylacetone as a superior marker compared to tyrosine for early identification of tyrosinemia type I.
Early diagnosis coupled with prompt initiation of 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione (NTBC) and dietary management was established as essential to prevent acute liver failure and long-term complications.
The expert panel formulated uniform clinical protocols detailing immediate diagnostic confirmation and lifelong multidisciplinary follow-up for both screen-positive and symptomatically diagnosed individuals.